Ra Pharmaceuticals Receives $58,500,000 Series B Round

  • Feed Type
  • Date
    7/23/2015
  • Company Name
    Ra Pharmaceuticals
  • Mailing Address
    One Kendall Square Cambridge, MA 02139 USA
  • Company Description
    Ra Pharmaceuticals is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma’s peptide-like molecules are highly-stable, synthetic products with chemical structures that offer intrinsic cell permeability.
  • Website
    http://www.rapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $58,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds of the financing will be used to generate human proof of concept data for its lead molecule, RA101495, in multiple indications.
  • M&A Terms
  • Venture Investor
    RA Capital
  • Venture Investor
    Novo Ventures
  • Venture Investor
    Lightstone Ventures
  • Venture Investor
    Rock Springs Capital
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Morgenthaler Ventures
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Limulus Venture Partners

Trending on Xconomy